180 related articles for article (PubMed ID: 12932930)
1. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer.
Nord C; Bjøro T; Ellingsen D; Mykletun A; Dahl O; Klepp O; Bremnes RM; Wist E; Fosså SD
Eur Urol; 2003 Sep; 44(3):322-8. PubMed ID: 12932930
[TBL] [Abstract][Full Text] [Related]
2. Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones.
Aschim EL; Oldenburg J; Kristiansen W; Giwercman A; Witczak O; Fosså SD; Haugen TB
Hum Reprod; 2014 Dec; 29(12):2844-51. PubMed ID: 25336703
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors.
Sprauten M; Brydøy M; Haugnes HS; Cvancarova M; Bjøro T; Bjerner J; Fosså SD; Oldenburg J
J Clin Oncol; 2014 Feb; 32(6):571-8. PubMed ID: 24419125
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
[TBL] [Abstract][Full Text] [Related]
5. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors.
Sprauten M; Haugnes HS; Brydøy M; Kiserud C; Tandstad T; Bjøro T; Bjerner J; Cvancarova M; Fosså SD; Oldenburg J
Ann Oncol; 2015 Oct; 26(10):2133-40. PubMed ID: 26265167
[TBL] [Abstract][Full Text] [Related]
6. Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome.
Bogefors C; Isaksson S; Bobjer J; Kitlinski M; Leijonhufvud I; Link K; Giwercman A
Andrology; 2017 Jul; 5(4):711-717. PubMed ID: 28544654
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment.
Steggink LC; van Beek AP; Boer H; Meijer C; Lubberts S; Oosting SF; de Jong IJ; van Ginkel RJ; Lefrandt JD; Gietema JA; Nuver J
Andrology; 2019 Jul; 7(4):441-448. PubMed ID: 30609309
[TBL] [Abstract][Full Text] [Related]
8. Hypogonadism risk in men treated for childhood cancer.
Romerius P; Ståhl O; Moëll C; Relander T; Cavallin-Ståhl E; Wiebe T; Giwercman YL; Giwercman A
J Clin Endocrinol Metab; 2009 Nov; 94(11):4180-6. PubMed ID: 19789207
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors.
Kurobe M; Kawai K; Suetomi T; Iwamoto T; Waku N; Kawahara T; Kojima T; Joraku A; Miyazaki J; Nishiyama H
Int J Urol; 2018 May; 25(5):457-462. PubMed ID: 29478250
[TBL] [Abstract][Full Text] [Related]
10. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
11. Chronic cancer-related fatigue in long-term survivors of testicular cancer.
Orre IJ; Fosså SD; Murison R; Bremnes R; Dahl O; Klepp O; Loge JH; Wist E; Dahl AA
J Psychosom Res; 2008 Apr; 64(4):363-71. PubMed ID: 18374735
[TBL] [Abstract][Full Text] [Related]
12. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer.
Petersen PM; Skakkebaek NE; Vistisen K; Rørth M; Giwercman A
J Clin Oncol; 1999 Mar; 17(3):941-7. PubMed ID: 10071288
[TBL] [Abstract][Full Text] [Related]
13. Thyroid hypofunction in aging testicular cancer survivors.
Nome RV; Småstuen MC; Fosså SD; Kiserud CE; Åsvold BO; Bjøro T
Acta Oncol; 2021 Nov; 60(11):1452-1458. PubMed ID: 34351829
[TBL] [Abstract][Full Text] [Related]
14. Hypogonadism and androgen deficiency symptoms in testicular cancer survivors.
Lackner JE; Märk I; Schatzl G; Marberger M; Kratzik C
Urology; 2007 Apr; 69(4):754-8. PubMed ID: 17445664
[TBL] [Abstract][Full Text] [Related]
15. Hypogonadism and fertility issues following primary treatment for testicular cancer.
Oldenburg J
Urol Oncol; 2015 Sep; 33(9):407-12. PubMed ID: 25736189
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
17. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
[TBL] [Abstract][Full Text] [Related]
18. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.
Gerl A; Mühlbayer D; Hansmann G; Mraz W; Hiddemann W
Cancer; 2001 Apr; 91(7):1297-303. PubMed ID: 11283930
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction.
Skøtt JW; Lauritsen J; Kreiberg M; Daugaard G; Bandak M
Clin Genitourin Cancer; 2019 Feb; 17(1):e65-e71. PubMed ID: 30293923
[TBL] [Abstract][Full Text] [Related]
20. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.
Brennemann W; Stoffel-Wagner B; Helmers A; Mezger J; Jäger N; Klingmüller D
J Urol; 1997 Sep; 158(3 Pt 1):844-50. PubMed ID: 9258096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
